Cargando…

Prevalence and molecular basis of glucose-6-phosphate dehydrogenase deficiency in Afghan populations: implications for treatment policy in the region

BACKGROUND: Glucose-6-phosphate dehydrogenase deficiency (G6PD), an x-linked inherited enzymopathy, is a barrier to malaria control because primaquine cannot be readily applied for radical cure in individuals with the condition. In endemic areas, including in Afghanistan, the G6PD status of vivax pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Leslie, Toby, Moiz, Bushra, Mohammad, Nader, Amanzai, Omar, ur Rasheed, Haroon, Jan, Sakhi, Siddiqi, Abdul M, Nasir, Amna, Beg, Mohammad A, Vink, Martijn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710480/
https://www.ncbi.nlm.nih.gov/pubmed/23834949
http://dx.doi.org/10.1186/1475-2875-12-230
_version_ 1782276875686510592
author Leslie, Toby
Moiz, Bushra
Mohammad, Nader
Amanzai, Omar
ur Rasheed, Haroon
Jan, Sakhi
Siddiqi, Abdul M
Nasir, Amna
Beg, Mohammad A
Vink, Martijn
author_facet Leslie, Toby
Moiz, Bushra
Mohammad, Nader
Amanzai, Omar
ur Rasheed, Haroon
Jan, Sakhi
Siddiqi, Abdul M
Nasir, Amna
Beg, Mohammad A
Vink, Martijn
author_sort Leslie, Toby
collection PubMed
description BACKGROUND: Glucose-6-phosphate dehydrogenase deficiency (G6PD), an x-linked inherited enzymopathy, is a barrier to malaria control because primaquine cannot be readily applied for radical cure in individuals with the condition. In endemic areas, including in Afghanistan, the G6PD status of vivax patients is not routinely determined so the drug is rarely, if ever, prescribed even though it is included as a recommended treatment in local, regional and global guidelines. This study assessed the prevalence and genotype of G6PD deficiency in Afghan populations and examined the need for routine G6PD testing as a malaria treatment and control tool. METHODS: A cross-sectional household survey was conducted using random sampling in five Afghan cities to determine the prevalence of G6PD deficiency in Afghan ethnic groups. Filter-paper blood spots were analysed for phenotypic G6PD deficiency using a fluorescent spot test. Molecular analysis was conducted to identify the genetic basis of the disorder. RESULTS: Overall, 45/1,436 (3.1%) people were G6PD deficient, 36/728 (5.0%) amongst males and 9/708 (1.3%) amongst females. Amongst males the prevalence was highest in the Pashtun ethnic group (10%, 26/260) while in Tajik males it was 8/250 (3.2%); in Hazara males it was 1/77 (1.3%) and in Uzbek males is was 0/125. Genetic testing in those with deficiency showed that all were of the Mediterranean type (Med-) characterized by a C-T change at codon 563 of the G6PD gene. CONCLUSION: Prevalence of G6PD deficiency in Afghanistan varies considerably by ethnic group and is predominantly of the Mediterranean type. G6PD deficient individuals are susceptible to potentially severe and life-threatening haemolysis after standard primaquine treatment. If the aim of increasing access to radical treatment of vivax is to be successful reliable G6PD testing needs to be made routinely available within the health system.
format Online
Article
Text
id pubmed-3710480
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37104802013-07-14 Prevalence and molecular basis of glucose-6-phosphate dehydrogenase deficiency in Afghan populations: implications for treatment policy in the region Leslie, Toby Moiz, Bushra Mohammad, Nader Amanzai, Omar ur Rasheed, Haroon Jan, Sakhi Siddiqi, Abdul M Nasir, Amna Beg, Mohammad A Vink, Martijn Malar J Research BACKGROUND: Glucose-6-phosphate dehydrogenase deficiency (G6PD), an x-linked inherited enzymopathy, is a barrier to malaria control because primaquine cannot be readily applied for radical cure in individuals with the condition. In endemic areas, including in Afghanistan, the G6PD status of vivax patients is not routinely determined so the drug is rarely, if ever, prescribed even though it is included as a recommended treatment in local, regional and global guidelines. This study assessed the prevalence and genotype of G6PD deficiency in Afghan populations and examined the need for routine G6PD testing as a malaria treatment and control tool. METHODS: A cross-sectional household survey was conducted using random sampling in five Afghan cities to determine the prevalence of G6PD deficiency in Afghan ethnic groups. Filter-paper blood spots were analysed for phenotypic G6PD deficiency using a fluorescent spot test. Molecular analysis was conducted to identify the genetic basis of the disorder. RESULTS: Overall, 45/1,436 (3.1%) people were G6PD deficient, 36/728 (5.0%) amongst males and 9/708 (1.3%) amongst females. Amongst males the prevalence was highest in the Pashtun ethnic group (10%, 26/260) while in Tajik males it was 8/250 (3.2%); in Hazara males it was 1/77 (1.3%) and in Uzbek males is was 0/125. Genetic testing in those with deficiency showed that all were of the Mediterranean type (Med-) characterized by a C-T change at codon 563 of the G6PD gene. CONCLUSION: Prevalence of G6PD deficiency in Afghanistan varies considerably by ethnic group and is predominantly of the Mediterranean type. G6PD deficient individuals are susceptible to potentially severe and life-threatening haemolysis after standard primaquine treatment. If the aim of increasing access to radical treatment of vivax is to be successful reliable G6PD testing needs to be made routinely available within the health system. BioMed Central 2013-07-08 /pmc/articles/PMC3710480/ /pubmed/23834949 http://dx.doi.org/10.1186/1475-2875-12-230 Text en Copyright © 2013 Leslie et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Leslie, Toby
Moiz, Bushra
Mohammad, Nader
Amanzai, Omar
ur Rasheed, Haroon
Jan, Sakhi
Siddiqi, Abdul M
Nasir, Amna
Beg, Mohammad A
Vink, Martijn
Prevalence and molecular basis of glucose-6-phosphate dehydrogenase deficiency in Afghan populations: implications for treatment policy in the region
title Prevalence and molecular basis of glucose-6-phosphate dehydrogenase deficiency in Afghan populations: implications for treatment policy in the region
title_full Prevalence and molecular basis of glucose-6-phosphate dehydrogenase deficiency in Afghan populations: implications for treatment policy in the region
title_fullStr Prevalence and molecular basis of glucose-6-phosphate dehydrogenase deficiency in Afghan populations: implications for treatment policy in the region
title_full_unstemmed Prevalence and molecular basis of glucose-6-phosphate dehydrogenase deficiency in Afghan populations: implications for treatment policy in the region
title_short Prevalence and molecular basis of glucose-6-phosphate dehydrogenase deficiency in Afghan populations: implications for treatment policy in the region
title_sort prevalence and molecular basis of glucose-6-phosphate dehydrogenase deficiency in afghan populations: implications for treatment policy in the region
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710480/
https://www.ncbi.nlm.nih.gov/pubmed/23834949
http://dx.doi.org/10.1186/1475-2875-12-230
work_keys_str_mv AT leslietoby prevalenceandmolecularbasisofglucose6phosphatedehydrogenasedeficiencyinafghanpopulationsimplicationsfortreatmentpolicyintheregion
AT moizbushra prevalenceandmolecularbasisofglucose6phosphatedehydrogenasedeficiencyinafghanpopulationsimplicationsfortreatmentpolicyintheregion
AT mohammadnader prevalenceandmolecularbasisofglucose6phosphatedehydrogenasedeficiencyinafghanpopulationsimplicationsfortreatmentpolicyintheregion
AT amanzaiomar prevalenceandmolecularbasisofglucose6phosphatedehydrogenasedeficiencyinafghanpopulationsimplicationsfortreatmentpolicyintheregion
AT urrasheedharoon prevalenceandmolecularbasisofglucose6phosphatedehydrogenasedeficiencyinafghanpopulationsimplicationsfortreatmentpolicyintheregion
AT jansakhi prevalenceandmolecularbasisofglucose6phosphatedehydrogenasedeficiencyinafghanpopulationsimplicationsfortreatmentpolicyintheregion
AT siddiqiabdulm prevalenceandmolecularbasisofglucose6phosphatedehydrogenasedeficiencyinafghanpopulationsimplicationsfortreatmentpolicyintheregion
AT nasiramna prevalenceandmolecularbasisofglucose6phosphatedehydrogenasedeficiencyinafghanpopulationsimplicationsfortreatmentpolicyintheregion
AT begmohammada prevalenceandmolecularbasisofglucose6phosphatedehydrogenasedeficiencyinafghanpopulationsimplicationsfortreatmentpolicyintheregion
AT vinkmartijn prevalenceandmolecularbasisofglucose6phosphatedehydrogenasedeficiencyinafghanpopulationsimplicationsfortreatmentpolicyintheregion